Abstract
Deficiency in the enzyme adenosine deaminase (ADA) in humans manifests primarily as severe lymphopenia and immunodeficiency, resulting in death by 6 months of age, if untreated. In this review, we discuss phenotypical, biochemical, and metabolic hallmarks of the disease, and describe a mouse model in which levels of ADA can be biochemically and genetically manipulated. This model provides exciting possibilities for uncovering the mechanisms by which this purine catabolic enzyme affects lymphopoiesis.
Copyright 2000 Academic Press.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adenosine / metabolism
-
Adenosine Deaminase / deficiency*
-
Adenosine Deaminase / genetics
-
Adenosine Deaminase / metabolism*
-
Adenosine Deaminase / pharmacology
-
Animals
-
Deoxyadenosines / metabolism
-
Disease Models, Animal
-
Humans
-
Lymphocytes / drug effects
-
Lymphocytes / enzymology*
-
Lymphocytes / immunology*
-
Lymphocytes / metabolism
-
Mice
-
Severe Combined Immunodeficiency / enzymology*
-
Severe Combined Immunodeficiency / immunology*
-
Severe Combined Immunodeficiency / physiopathology
-
Severe Combined Immunodeficiency / therapy
Substances
-
Deoxyadenosines
-
Adenosine Deaminase
-
Adenosine